SK19192000A3 - Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia - Google Patents

Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia Download PDF

Info

Publication number: SK19192000A3
Authority: SK; Slovakia
Prior art keywords: paroxetine; pharmaceutically acceptable; core; substance; acceptable salt
Prior art date: 1998-06-16

Application number

SK1919-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Martin X. Steiner

Original Assignee

Smithkline Beecham Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-16

Filing date

1999-06-16

Publication date

2001-05-10

1999-06-16 Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation

2001-05-10 Publication of SK19192000A3 publication Critical patent/SK19192000A3/sk

Links

238000000034 method Methods 0.000 title abstract description 9
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims abstract description 65
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims abstract description 40
229960002296 paroxetine Drugs 0.000 claims abstract description 40
150000003839 salts Chemical class 0.000 claims abstract description 17
230000005586 smoking cessation Effects 0.000 claims abstract description 12
239000012453 solvate Substances 0.000 claims abstract description 11
230000000391 smoking effect Effects 0.000 claims abstract description 10
239000000126 substance Substances 0.000 claims description 48
239000000203 mixture Substances 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
238000009472 formulation Methods 0.000 claims description 14
229960005183 paroxetine hydrochloride Drugs 0.000 claims description 13
239000012458 free base Substances 0.000 claims description 9
230000003111 delayed effect Effects 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
239000012530 fluid Substances 0.000 claims description 5
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
229960002715 nicotine Drugs 0.000 claims description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
230000036571 hydration Effects 0.000 claims description 2
238000006703 hydration reaction Methods 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
230000001737 promoting effect Effects 0.000 abstract description 5
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
239000003826 tablet Substances 0.000 description 33
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
235000019359 magnesium stearate Nutrition 0.000 description 16
229920000642 polymer Polymers 0.000 description 14
238000013270 controlled release Methods 0.000 description 11
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
239000001267 polyvinylpyrrolidone Substances 0.000 description 11
229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
230000002209 hydrophobic effect Effects 0.000 description 10
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
229960001375 lactose Drugs 0.000 description 7
239000008101 lactose Substances 0.000 description 7
229960001021 lactose monohydrate Drugs 0.000 description 7
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
229920003091 Methocel™ Polymers 0.000 description 6
239000000017 hydrogel Substances 0.000 description 6
239000012729 immediate-release (IR) formulation Substances 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
238000003860 storage Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
229920003094 Methocel™ K4M Polymers 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000004040 coloring Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000009492 tablet coating Methods 0.000 description 4
239000002700 tablet coating Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920000148 Polycarbophil calcium Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
229940095498 calcium polycarbophil Drugs 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
229920003109 sodium starch glycolate Polymers 0.000 description 3
239000008109 sodium starch glycolate Substances 0.000 description 3
229940079832 sodium starch glycolate Drugs 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000007894 caplet Substances 0.000 description 2
235000013339 cereals Nutrition 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
239000001069 triethyl citrate Substances 0.000 description 2
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
235000013769 triethyl citrate Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920003159 Eudragit® RS 100 Polymers 0.000 description 1
208000011688 Generalised anxiety disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
-1 Iecithin Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920003093 Methocel™ K100 LV Polymers 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000029364 generalized anxiety disease Diseases 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000012552 review Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229940045860 white wax Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Addiction (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1919-2000A 1998-06-16 1999-06-16 Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia SK19192000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9812941.4A GB9812941D0 (en)	1998-06-16	1998-06-16	Method of treatment
PCT/US1999/013623 WO1999065491A1 (en)	1998-06-16	1999-06-16	Method of treatment

Publications (1)

Publication Number	Publication Date
SK19192000A3 true SK19192000A3 (sk)	2001-05-10

Family

ID=10833832

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1919-2000A SK19192000A3 (sk)	1998-06-16	1999-06-16	Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia

Country Status (20)

Country	Link
EP (1)	EP1087766A4 (cs)
JP (1)	JP2002518330A (cs)
KR (1)	KR20010052895A (cs)
CN (1)	CN1305379A (cs)
AP (1)	AP2000002002A0 (cs)
AU (1)	AU740749B2 (cs)
BG (1)	BG105127A (cs)
BR (1)	BR9911150A (cs)
CA (1)	CA2335236A1 (cs)
CZ (1)	CZ20004698A3 (cs)
EA (1)	EA003584B1 (cs)
GB (1)	GB9812941D0 (cs)
HU (1)	HUP0102507A3 (cs)
IL (1)	IL139943A0 (cs)
NO (1)	NO20006383L (cs)
NZ (1)	NZ508532A (cs)
PL (1)	PL345261A1 (cs)
SK (1)	SK19192000A3 (cs)
WO (1)	WO1999065491A1 (cs)
ZA (1)	ZA200007396B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0303827A2 (hu) *	2000-08-28	2004-04-28	Synthon B.V.	Paroxetinkészítmények és eljárások ezek előállítására
EP1465601A4 (en)	2001-12-28	2006-02-15	Teva Pharma	STABLE PHARMACEUTICAL FORMULATION OF PAROXETINE ANHYDROUS HYDROCHLORIDE AND PREPARATION METHOD
WO2006023347A1 (en) *	2004-08-20	2006-03-02	Alpharma, Inc.	Paroxetine formulations
FR2926221A1 (fr) *	2008-01-14	2009-07-17	Tassin Thomas	Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2058061T3 (es) *	1985-10-25	1994-11-01	Beecham Group Plc	Derivado de piperidina, su preparacion y su uso como medicamento.
WO1992009281A2 (en) *	1990-11-24	1992-06-11	Beecham Group Plc	Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
SK283608B6 (sk) *	1995-02-06	2003-10-07	Smithkline Beecham Plc	Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB9605828D0 (en) *	1996-03-20	1996-05-22	Smithkline Beecham Plc	Treatment method

1998
- 1998-06-16 GB GBGB9812941.4A patent/GB9812941D0/en not_active Ceased
1999
- 1999-06-16 AU AU46885/99A patent/AU740749B2/en not_active Ceased
- 1999-06-16 AP APAP/P/2000/002002A patent/AP2000002002A0/en unknown
- 1999-06-16 EA EA200100041A patent/EA003584B1/ru not_active IP Right Cessation
- 1999-06-16 CN CN99807465A patent/CN1305379A/zh active Pending
- 1999-06-16 NZ NZ508532A patent/NZ508532A/en unknown
- 1999-06-16 BR BR9911150-0A patent/BR9911150A/pt not_active Application Discontinuation
- 1999-06-16 JP JP2000554371A patent/JP2002518330A/ja not_active Withdrawn
- 1999-06-16 PL PL99345261A patent/PL345261A1/xx not_active Application Discontinuation
- 1999-06-16 SK SK1919-2000A patent/SK19192000A3/sk unknown
- 1999-06-16 IL IL13994399A patent/IL139943A0/xx unknown
- 1999-06-16 KR KR1020007014240A patent/KR20010052895A/ko not_active Withdrawn
- 1999-06-16 EP EP99930327A patent/EP1087766A4/en not_active Withdrawn
- 1999-06-16 WO PCT/US1999/013623 patent/WO1999065491A1/en not_active Ceased
- 1999-06-16 CA CA002335236A patent/CA2335236A1/en not_active Abandoned
- 1999-06-16 CZ CZ20004698A patent/CZ20004698A3/cs unknown
- 1999-06-16 HU HU0102507A patent/HUP0102507A3/hu unknown
2000
- 2000-12-12 ZA ZA200007396A patent/ZA200007396B/xx unknown
- 2000-12-14 NO NO20006383A patent/NO20006383L/no unknown
2001
- 2001-01-08 BG BG105127A patent/BG105127A/xx unknown

Also Published As

Publication number	Publication date
CZ20004698A3 (cs)	2002-02-13
HUP0102507A2 (hu)	2002-05-29
EP1087766A4 (en)	2001-11-21
ZA200007396B (en)	2002-02-27
JP2002518330A (ja)	2002-06-25
PL345261A1 (en)	2001-12-03
NZ508532A (en)	2003-08-29
EA200100041A1 (ru)	2001-06-25
EP1087766A1 (en)	2001-04-04
CA2335236A1 (en)	1999-12-23
WO1999065491A1 (en)	1999-12-23
AU740749B2 (en)	2001-11-15
BR9911150A (pt)	2001-03-06
HUP0102507A3 (en)	2003-12-29
KR20010052895A (ko)	2001-06-25
AP2000002002A0 (en)	2000-12-31
NO20006383D0 (no)	2000-12-14
IL139943A0 (en)	2002-02-10
NO20006383L (no)	2000-12-14
GB9812941D0 (en)	1998-08-12
CN1305379A (zh)	2001-07-25
BG105127A (en)	2001-11-30
AU4688599A (en)	2000-01-05
EA003584B1 (ru)	2003-06-26

Publication	Publication Date	Title
JP5421775B2 (ja)	2014-02-19	オキシコドンを含む顆粒及び口腔内崩壊錠剤
US5814339A (en)	1998-09-29	Film coated tablet of paracetamol and domperidone
US20040220250A1 (en)	2004-11-04	Novel oral dosage form for carvedilol
CA2314433A1 (en)	1999-06-17	Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance
US6855336B2 (en)	2005-02-15	Omeprazole formulation
IL107354A (en)	1998-02-08	Film-coated extended release oral dosage composition
JP2002509882A (ja)	2002-04-02	フルオキセチンおよびそのエナンチオマーの安定した投薬剤形
US20060153925A1 (en)	2006-07-13	Novel solid pharmaceutical composition comprising amisulpride
RU2401109C2 (ru)	2010-10-10	Таблетированный препарат с замедленным высвобождением для вертиго
AU2005204014B2 (en)	2008-02-28	Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
US6300343B1 (en)	2001-10-09	Method of treatment
SK19192000A3 (sk)	2001-05-10	Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
US20020173522A1 (en)	2002-11-21	Pharmaceutical compositions comprising norastemizole
MXPA00012626A (en)	2001-07-31	Method of treatment
WO1998042379A2 (en)	1998-10-01	Chemically and thermally stable norastemizole formulations
HK1125857B (en)	2018-07-27	Granule and orally disintegrating tablet comprising oxycodone
HK1125857A (en)	2009-08-21	Granule and orally disintegrating tablet comprising oxycodone
HK1010687B (en)	2003-09-11	Film coated tablet of paracetamol and domperidone